The Patient Impact of 10 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Data From the Phase III OPERA and ORATORIO Studies
Preserving patient fucntion, by optimally slowing disease progression, is important to people with MS and is a key treatment goal. The 10 year long-term impact of ocrelizumab on disability in patients with RMS and PPMS from the OLEs of the OPERA I/II (NCT) and ORARTORIO trials (NCT) respectively, are analysed. Disability progression, defined by several clinical measures, is reported in RMS and PPMS patients treated who initiated ocrelizumab treatment early, compared to delayed ocrelizumab treatment.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.